- Conditions
- Mild Cognitive Impairment Due to Alzheimer's Disease
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Sun City, Arizona • San Diego, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 7,067
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Spinocerebellar Ataxia Type 7, Spinocerebellar Ataxia Type 8, Spinocerebellar Ataxia Type 10, Spinocerebellar Ataxia Type 17, ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1
- Interventions
- CAD-1883, Placebos
- Drug
- Lead sponsor
- Cadent Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Long Beach, California • Los Angeles, California • Aurora, Colorado + 3 more
- Conditions
- Influenza
- Interventions
- Oseltamivir, MEDI8852, Placebo
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 22
- States / cities
- Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more
- Conditions
- Excessive Sleepiness
- Interventions
- armodafinil, placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 427 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Crestview, Kentucky • New York, New York + 1 more
- Conditions
- Schizophrenia
- Interventions
- vabicaserin, risperidone, placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 32
- States / cities
- Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more
- Conditions
- Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
- Interventions
- ExPEC9V, Placebo
- Biological · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 17,797 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 142
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Sun City West, Arizona + 100 more
- Conditions
- Atrial Fibrillation, Stroke, Embolism
- Interventions
- Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 295
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 18
- States / cities
- Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
- Conditions
- Short Bowel Syndrome
- Interventions
- Teduglutide, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Glaucoma, Open-angle, Ocular Hypertension
- Interventions
- 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584, Matching Placebo, Latanoprost 0.005%
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Artesia, California • Inglewood, California + 5 more
- Conditions
- Depressive Disorder, Major, Anhedonia
- Interventions
- Aticaprant, Placebo
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Efpeglenatide SAR439977, Placebo, Background therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 18 more
- Conditions
- Parkinson's Disease
- Interventions
- MEDI1341, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Myocardial Ischemia, Coronary Artery Disease, Arteriosclerosis, Chronic Stable Angina
- Interventions
- Ranolazine, Placebo
- Drug
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- COVID-19
- Interventions
- Rivaroxaban, Placebo
- Drug
- Lead sponsor
- Gates Medical Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 497 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 17
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more
- Conditions
- Nutritional Stunting, Growth Failure
- Interventions
- Essential Amino Acid (EAA) group, Placebo
- Dietary Supplement
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Cystic Fibrosis
- Interventions
- VX-809, Placebo, VX-770
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
- Conditions
- Obesity
- Interventions
- Tirzepatide, Risedronate, Placebo
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Healthy Subjects
- Interventions
- Placebo, PB 718
- Drug
- Lead sponsor
- PegBio Co., Ltd.
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Alopecia Areata
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Lubiprostone, Placebo
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
- Conditions
- Pruritus, Psoriasis
- Interventions
- 5 mg Serlopitant Tablets, Matching Placebo Tablets
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 39
- States / cities
- Bryant, Arkansas • Beverly Hills, California • Fremont, California + 32 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- Nicotine Transdermal Patch, Placebo Patch
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 36
- States / cities
- Scottsdale, Arizona • North Little Rock, Arkansas • Downey, California + 31 more
- Conditions
- Treatment Resistant Depression
- Interventions
- ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
- Drug
- Lead sponsor
- Alar Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more